GB2458467A - Dietary supplement for maintenance of bone health - Google Patents
Dietary supplement for maintenance of bone health Download PDFInfo
- Publication number
- GB2458467A GB2458467A GB0804968A GB0804968A GB2458467A GB 2458467 A GB2458467 A GB 2458467A GB 0804968 A GB0804968 A GB 0804968A GB 0804968 A GB0804968 A GB 0804968A GB 2458467 A GB2458467 A GB 2458467A
- Authority
- GB
- United Kingdom
- Prior art keywords
- vitamin
- omega
- fatty acids
- pharmaceutical composition
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000037180 bone health Effects 0.000 title claims abstract description 38
- 238000012423 maintenance Methods 0.000 title claims description 32
- 235000015872 dietary supplement Nutrition 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 76
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 51
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 42
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 42
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 42
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 42
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 42
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000011575 calcium Substances 0.000 claims abstract description 41
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 41
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 41
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 41
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 38
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 38
- 239000011718 vitamin C Substances 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 36
- 235000003687 soy isoflavones Nutrition 0.000 claims abstract description 36
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011777 magnesium Substances 0.000 claims abstract description 31
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 31
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011701 zinc Substances 0.000 claims abstract description 28
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 28
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims abstract description 27
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000011669 selenium Substances 0.000 claims abstract description 23
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 23
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910052802 copper Inorganic materials 0.000 claims abstract description 21
- 239000010949 copper Substances 0.000 claims abstract description 21
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229910052796 boron Inorganic materials 0.000 claims abstract description 20
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 10
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 10
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 4
- 235000001465 calcium Nutrition 0.000 claims description 40
- 235000021323 fish oil Nutrition 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000470 constituent Substances 0.000 claims description 10
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 4
- 235000021388 linseed oil Nutrition 0.000 claims 4
- 239000000944 linseed oil Substances 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract description 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract description 4
- 150000007513 acids Chemical class 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 8
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition maintaining bone health, for combined, sequential or simultaneous administration consists of calcium, magnesium, zinc, vitamin D3, manganese, selenium, copper, boron; vitamin C, vitamin D3, soy isoflavone, and omega-3 fatty acids. The fatty acids are preferably DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid). Preferably the vitamin C, vitamin D3, soy isoflavone and omega-3 acids are administered in a capsule and the other components are administered as 2 tablets.
Description
Page 1
DESCRIPTION OF INVENTION
Title: Composition for bone health maintenance
TECHNICAL FIELD
This invention concerns a composition of biochemical and nutraceutical constituents for use in the maintenance of bone health, and the prevention of Osteoporosis.
BACKGROUND ART
Currently, in the U.K., more than three million people over the age of 50 suffer from Osteoporosis with an annual cost to the NHS of more than �2 billion.
The trend away from dairy foods, particularly among young women and a lack of exercise, most notably weight bearing exercise, has resulted in an increased incidence of bone health problems. Against the backdrop of an ageing population, with the percentage of adults aged fifty plus growing from currently around 30% to a predicted 41% in 2030, the problem is set to get much worse.
The general trend towards more healthy eating has resulted in the fortification of some functional food products with additional calcium and/or vitamin D. Vitamin D in particular has been receiving considerable press coverage in relation to its health benefits.
Those in primary need of bone health nutrients are women diagnosed with low Page 2 bone density or osteoporosis, and all older women (45 years old or older), who are concerned about osteoporosis as they fall within a higher risk category (smokers, family history, low calcium consumption, underweight, over 50 not on HRT, going through menopause etc).
Those in secondary need are breast feeding women who have a greater need for additional calcium, women between the ages of 20 and 40, the health conscious, and people who avoid dairy products.
Those in tertiary need are women over the age of 30 who aware of the need to take calcium from a prevention viewpoint.
DISCLOSURE OF INVENTION
This invention concerns a novel dual tablet and capsule formulation aimed at supplementing the diet in order to provide constituents that will optimise the health of the bones. The foiiowiiig is the optimal formulation -Daily dosages of the following constituents, provided in 2 tablets per day: Calcium -800 mg Magnesium -300 mg Zinc-10mg Vitamin D3 -Smcg (200 I.U.) Manganese -0.5 mg Selenium -50 mcg Copper -1 mg Page 3 Boron-0.6mg Plus, daily dosages of the following constituents provided in I capsule per day: Vitamin C -100mg Vitamin D3 -l0mcg (400 I.U.) Soy Isoflavone -100mg Omega-3 fatty acids (from Fish Oil) -350mg, providing 175mg DFIA (Docosahexaenpoic acid) and 35mg EPA (Eicosapentaenoic acid) RDA / Active Levels: The following are the recommended dietary allowances for some of the constituents, and the reasons for the level chosen.
Calcium -100% -Full RDA provided for this key mineral.
Magnesium -100% -Full RDA provided for this key mineral Zmc --Seldom mcluded in other bone neaim formulae.
Vitamin D3 -300% -The critical importance of vitamin D has been recently highlighted by research and health organisations. It is likely that the current RDA will be increased in the future to reflect new research data.
Manganese -RDA not established Selenium -RDA not established Page 4 Copper -RDA not established Boron -RDA not established Omega-3 fatty acids -RDA not established Vitamin C -167% RDA Soy Isoflavone Extract -RDA not established Relevance of constituents The composition provides a significant dietary level of nutrients and ensures that supplemental intake is within safety levels to help maintain healthy bones.
It provides a rich source of calcium and an optimal balance of cofactors to help maintain strong bones and teeth, as well as the health of the heart, muscles and nerves. Constituents are included to optimise bone health for the following reasons: The primary role of Calcium in the body is its structural role in bones and teeth.
Calcium is also essential for cellular structure, nerve signal transmission and metabolic function.
Vitamin D3, a fat soluble vitamin, is required for calcium metabolism, calcium absorption and deposition in bones. The formulation contains the preferred D3 form of Vitamin D which is a specific form made in the human body and Page 5 therefore more effective than D2, which is found in some formulations.
Vitamin D is converted to a vital calcium-controlling hormone (1,25 -dihydroxycholecalciferol). All its functions are related to this hormone's effects.
Magnesium is essential for bone metabolism and calcium homeostasis is partly controlled by a mechanism that requires Magnesium.
Zinc has been found to be involved in DNA and RNA synthesis, bone growth, protein metabolism, and in many other enzymes.
Manganese plays an important role in regulating calcium metabolism and can therefore work to maintain bone mineralisation.
Selenium is important for antioxidant systems to defend bone cells against free radical attack.
Copper is required for cross-linking of collagen -necessaiy for the formulation of cartilage, which cushions and supports bones.
Boron is essential for the utilisation of vitamin D, which enhances the absorption of calcium. Recent research demonstrates that boron may be essential in the conversion of vitamin D to its active fonu.
Omega-3 fatty acids (from Fish Oil) are a source of the essential fatty acids DHA (Docosahexaenoic acid) and EPA (Eicosapentaenoic acid), which have been shown to play an important role in bone health.
Page 6 Soy Isoflavone is included to provide healthy bone density.
Vitamin C is a major antioxidant that contributes to bone matrix formation through its role in the development of collagen.
Suggested Daily Intake: The 2 tablets and 1 capsule are best taken with a main meal with a full glass of water or a cold drink.
Recommended Contra -Indications/Warnings: It is recommended to take the 2 tablets and 1 capsule together with a main meal, in order to ensure maximum absorption of nutrients and avoid nausea, which can occur when taking any tablets on an empty stomach.
Do not exceed the recommended intake. Levels included in formula ensure supplemental intake is within safety levels.
INDUSTRIAL APPLICABILITY
According to this invention, there is a pharmaceutical composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that pharmaceutical composition for combined, Page 7 sequential or simultaneous administration, in any form, via any route, for use in the maintenance of bone health. In its optimal form it consists of a daily intake of 2 tablets that in total consist of: 800mg Calcium, 300mg Magnesium, 10mg Zinc, 5mcg Vitamin D3, 0.5mg Manganese, 50mcg Selenium, 1mg Copper, 0.6mg Boron; plus 1 capsule that consists of 100mg Vitamin C, lomcg Vitamin D3, 100mg Soy Isoflavone, 350mg Omega-3 fatty acids (from Fish Oil).
Claims (28)
- Page 8CLAIMS1. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of approximately 800mg Calcium, 300mg Magnesium, 10mg Zinc, l5mcg Vitamin D3, 0.5mg Manganese, 50mcg Selenium, 1mg Copper, 0.6mg Boron, 100mg Vitamin C, 100mg Soy Isoflavone, and 350mg Omega-3 fatty acids.
- 2. A pharmaceutical composition for the maintenance of bone health, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of approximately 800mg Calcium, 300mg Magnesium, 10mg Zinc, l5mcg Vitamin D3, 0.5mg Manganese, 50mcg Selenium, 1mg Copper, 0.6mg Boron, 100mg Vitamin C, 100mg Soy Isoflavone, 350mg and Omega-3 fatty acids.
- 3. A pharmaceutical composition for the maintenance of bone health, for comhined.. sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of 600mg to 1000mg Calcium, 150mg to 450mg Magnesium, 5mg to 15mg Zinc, 5mcg to 25mcg Vitamin D3, 0.25mg to 1.0mg Manganese, 25mcg to 75mcg Selenium, 0.5mg to 1.5mg Copper, 0.3mg to 0.9mg Boron, 50mg to 200mg Vitamin C, 50mg to 150mg Soy Isoflavone, and 200mg to 500mg Omega-3 fatty acids.
- 4. A pharmaceutical composition for the maintenance of bone health, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 600mg to 1000mg Calcium, 150mg to 450mg Magnesium, 5mg to 15mg Zinc, 5mcg to 25mcg Page 9 Vitamin D3, 0.25mg to 1.0mg Manganese, 25mcg to 75mcg Selenium, 0.5mg to 1.5mg Copper, 0.3mg to 0.9mg Boron, 50mg to 200mg Vitamin C, 50mg to 150mg Soy Isoflavone, and 200mg to 1000mg Omega-3 fatty acids.
- 5. A pharmaceutical composition for the maintenance of bone health, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of Calcium, Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Boron, Vitamin C, Soy Isoflavone, and Omega-3 fatty acids.
- 6. A pharmaceutical composition for the maintenance of bone health, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Calcium, Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Boron, Vitamin C, Soy Isoflavone, and Omega-3 fatty acids.
- 7. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 50mg to 200mg Soy Isoflavones, 200mg to 1000mg Omega-3 fatty acids, 50mg to 150mg Vitamin C, and 5mcg to 25mcg Vitamin D3, in excess of 400mg Calcium, and one or more of Magnesium, Zinc, Manganese, Copper, Boron.
- 8. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, Vitamin C, Vitamin D3, an average daily dosage in excess of 400mg Calcium, and one or more of Magnesium, Zinc, Manganese, Copper, Boron.Page 10
- 9. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, Vitamin C, Vitamin D3 and Calcium, and one or more of Magnesium, Zinc, Manganese, Copper, Boron.
- 10. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 50mg to 200mg Soy Isoflavones, 200mg to 1000mg Omega-3 fatty acids, 50mg to 150mg Vitamin C, 5mcg to 25mcg Vitamin D3, and one or more of Calcium, Magnesium, Zinc, Manganese, Copper, Boron.
- 11. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, Vitamin C, Vitamin D3, and one or more of Calcium, Magnesium, Zinc, Manganese, Copper, Boron.
- 12. A pharmaceutical composition for bone health mamtenance, fbr combined, sequential or simultaneous administration, in any form, via any biological route, comprising 50mg to 200mg Soy Isoflavones, 200mg to 1000mg Omega-3 fatty acids, 50mg to I 50mg Vitamin C, and one or more of Vitamin D3, Calcium, Magnesium, Zinc, Manganese, Copper, Boron.
- 13. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, Vitamin C, and one or more of Vitamin D3, Calcium, Magnesium, Zinc, Manganese, Copper, Boron.Page 11
- 14. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 50mg to 200mg Soy Isoflavones, 200mg to 1000mg Omega-3 fatty acids, 50mg to 150mg Vitamin C, and 5mcg to 25mcg Vitamin D3, and in excess of 400mg Calcium.
- 15. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, Vitamin C, Vitamin D3 and in excess of 400mg Calcium.
- 16. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, Vitamin C, Vitamin D3 and Calcium.
- 17. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any fOrm, via any biological route, comprising 50mg to 200mg Soy Isoflavones, 200mg to 1000mg Omega-3 fatty acids, 50mg to 150mg Vitamin C, and Smcg to 25mcg Vitamin D3.
- 18. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, Vitamin C, and Vitamin D3.
- 19. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, Page 12 comprising 50mg to 200mg Soy Isoflavones, 200mg to 1000mg Omega-3 fatty acids, and 50mg to 150mg Vitamin C.
- 20. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Soy Isoflavones, Omega-3 fatty acids, and Vitamin C.
- 21. A claim according to any one of the previous claims in which the pharmaceutical composition does not comprise more than 300mg of amino acids in a protein or amino acid complex form.
- 22. A claim according to any one of the preceding claims in which another form of Vitamin D is used instead of Vitamin D3.
- 23. A claim according to any one of the preceding claims in which DHA (Docosahexaenpoic acid) and EPA (Eicosapentaenoic acid) are used instead of Omega-3 fatty acids.
- 24. A claim according to any one of the preceding claims in which flax seed oil or linseed oil is used instead of Omega-3 fatty acids from a marine source.
- 25. A pharmaceutical composition according to any one of the preceding claims for any use other than bone health maintenance.
- 26. A claim according to any one of the preceding claims in which the pharmaceutical composition includes one or more carriers or excipients.Page 13
- 27. The use in the manufacture of a medicament using a composition as described in Claims 1 to 26.
- 28. A method of treatment of bone disorders, using a pharmaceutical composition as described in Claims I to 26.Amendments to the claims have been filed as follows Page i'--CLAIMS1. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route.more than two thirds of which consists of Calcium, Soy Isoflavone and Boron, and which also consists essentially of Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Vitamin C, and Omega-3 fatty acids that are specifically derived from fish oil.2. A pharmaceutical composition for bone health maintenance, for combined, * :. sequential or simultaneous administration, in any form, via any biological route, more than two thirds of which consists of Calcium, Soy Isoflavone and Boron, * and which also comprises: Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Vitamin C, and Omega-3 fatty acids that are specifically ** derived from fish oil.S * S *5 *3. A phannaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, more than two thirds of which consists of Calcium, Soy Jsoflavone and Boron, and which also consists essentially of 300mg Magnesium, 10mg Zinc, l5mcg Vitamin D3, 0.5mg Manganese, 50mcg Selenium, 1mg Copper, 100mg Vitamin C, and 350mg Omega-3 fatty acids that are specifically derived from fish oil.4. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, more than two thirds of which consists of Calcium, Soy Isoflavone and Boron, and which also comorises 300mg Magnesium, 10mg Zinc, l5mcg Vitamin D3,SPage (5 0.5mg Manganese, S0mcg Selenium, 1mg Copper, 100mg Vitamin C, and 350mg Omega-3 fatty acids that are specifically derived from fish oil.5. A claim according to Claim 1 in which the range of average daily dosages are 600mg to 1000mg Calcium, 150mg to 450mg Magnesium, 5mg to 15mg Zinc, Smcg to 25mcg Vit2min D3, 0.25mg to 1.0mg Manganese, 25mcg to 75mcg Selenium, 0.5mg to 1.5mg Copper, 0.3mg to 0.9mg Boron, 50mg to 200mg Vitamin C, 50mg to 150mg Soy Isoflavone, and 200mg to 500mg Omega-3 fatty acids that are specifically derived from fish oil.:: 6. A claim according to Claim 2 in which the range of average daily dosages of the constituents when included are 600mg to 1000mg Calcium, 150mg to **: 450mg Magnesium, 5mg to 15mg Zinc, 5mcg to 25mcg Vitamin D3, 0.25mg to 1.0mg Manganese, 25mcg to 75mcg Selenium, 0.5mg to 1.5mg Copper, 0.3mg to 0.9mg Boron, 50mg to 200mg Vitamin C, 50mg to 150mg Soy Isoflavone, and 200mg to 500mg Omega-3 fatty acids that are specifically derived from fish oil.7. A claim according to Claim 5 in which the constituents are separated in to 2 tablets that include the Calcium, Magnesium, Zinc, some of the Vitamin D3, Manganese, Selenium, Copper, and Boron; plus 1 capsule that includes the Vitamin C, some of the Vitamin D3, Soy Isoflavone, and Omega-3 fatty acids (from Fish Oil).8. A claim according to Claim 6 in which the constituents are separated in to 2 tablets that include the Calcium, Magnesium, Zinc, some of the Vitamin D3, Manganese, Selenium, Copper, and Boron; plus 1 capsule that includes the Pagel(o Vitamin C, some of the Vitamin D3, Soy Isofiavone, and Omega-3 fatty acids (from Fish Oil).9. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, more than two thirds of which consists of Calcium and Soy Isoflavone, and which also comprises: Boron, Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Vitamin C, and Omega-3 fatty acids that are specifically derived from fish oil.::: 10. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, more than two thirds of which consists of Calcium and Soy Isoflavone, and which also consists essentially of Born, Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Vitamin C, and Omega-3 fatty acids that are * :. specifically derived from fish oil.11. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, the majority of which consists of Calcium, Soy Isoflavone and Boron, and which also comprises Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Vitamin C, and Omega-3 fatty acids that are specifically derived from fish oil.12. A pharmaceutical composition for bone health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route, the majority of which consists of Calcium and Soy Isoflavone, and which also Page 1 comprises two or more of: Boron, Magnesium, Zinc, Vitamin D3, Manganese, Selenium, Copper, Vitamin C, and Omega-3 fatty acids that are specifically derived from fish oil.13. A claim according to any one of claims 1 to 12 in which the pharmaceutical composition does not comprise more than 300mg of amino acids in a protein or amino acid complex form.14. A claim according to any one of claims 1 to 12 in which Vitamin D is used instead of Vitamin D3. S... * S S. S *.** 15. A claim according to any one of claims 1 to 12 in which DHA (Docosahexaenpoic acid) and EPA (Eicosapentaenoic acid) are specifically used *:. instead of Omega-3 fatty acids generally. S.16. A claim according to any one of claims 1 to 12 in which flax seed oil or * linseed oil is used instead of Omega-3 fatty acids from a marine source.17. A claim according to any one of claims I to 12 in which the pharmaceutical composition includes one or more carriers or excipients.18. The use in the manufacture of a medicament using a composition as described in any one of the preceding claims.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0804968A GB2458467A (en) | 2008-03-18 | 2008-03-18 | Dietary supplement for maintenance of bone health |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0804968A GB2458467A (en) | 2008-03-18 | 2008-03-18 | Dietary supplement for maintenance of bone health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0804968D0 GB0804968D0 (en) | 2008-04-16 |
| GB2458467A true GB2458467A (en) | 2009-09-23 |
Family
ID=39328306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0804968A Withdrawn GB2458467A (en) | 2008-03-18 | 2008-03-18 | Dietary supplement for maintenance of bone health |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2458467A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3005419A1 (en) * | 2013-05-13 | 2014-11-14 | Agronomique Inst Nat Rech | USE OF A COMBINATION OF TWO COMPOUNDS FOR THE TREATMENT AND / OR PREVENTION OF BONE DISORDERS |
| EP3090638A1 (en) * | 2015-04-20 | 2016-11-09 | Bernd-Michael Löffler | Nutritional supplement to treat signs of vitamin d3 deficiency |
| US20220160641A1 (en) * | 2015-10-09 | 2022-05-26 | Combocap, Inc. | Capsule with internal diaphragm for improved bioavailability |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190369A1 (en) * | 2002-04-09 | 2003-10-09 | Lovett William E. | Vitamin formulation for enhancing bone strength |
| DE20310493U1 (en) * | 2003-07-08 | 2003-10-23 | Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld | Micronutrient combination product for dietetic treatment of inflammatory-rheumatic diseases and osteoporosis, containing specific amounts of several vitamins, minerals, trace elements and antioxidants |
| DE202004013660U1 (en) * | 2004-09-01 | 2005-01-05 | Orthomol Pharmazeutische Vertriebs Gmbh | Vitamin-containing product for nutritional supplementation, useful in cases of cardiovascular disease, also promotes bone formation |
-
2008
- 2008-03-18 GB GB0804968A patent/GB2458467A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190369A1 (en) * | 2002-04-09 | 2003-10-09 | Lovett William E. | Vitamin formulation for enhancing bone strength |
| DE20310493U1 (en) * | 2003-07-08 | 2003-10-23 | Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld | Micronutrient combination product for dietetic treatment of inflammatory-rheumatic diseases and osteoporosis, containing specific amounts of several vitamins, minerals, trace elements and antioxidants |
| DE202004013660U1 (en) * | 2004-09-01 | 2005-01-05 | Orthomol Pharmazeutische Vertriebs Gmbh | Vitamin-containing product for nutritional supplementation, useful in cases of cardiovascular disease, also promotes bone formation |
Non-Patent Citations (5)
| Title |
|---|
| Am. J. Clin. Nut. (2007); 85:803-7 * |
| J. Clin. Endocrin. & Metab. (2003); 88:1048-1058 * |
| J. Clin. Endocrin. & Metab. (2003); 88:4740-4747 * |
| Obstet. Gynecol. (2007); 97: 109-15 * |
| Osteoporosis Int. (1997); 7:533-38 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3005419A1 (en) * | 2013-05-13 | 2014-11-14 | Agronomique Inst Nat Rech | USE OF A COMBINATION OF TWO COMPOUNDS FOR THE TREATMENT AND / OR PREVENTION OF BONE DISORDERS |
| WO2014184484A1 (en) * | 2013-05-13 | 2014-11-20 | Institut National De La Recherche Agronomique - Inra | Use of a combination of two compounds for the treatment and/or prevention of bone disorders |
| EP3090638A1 (en) * | 2015-04-20 | 2016-11-09 | Bernd-Michael Löffler | Nutritional supplement to treat signs of vitamin d3 deficiency |
| US20220160641A1 (en) * | 2015-10-09 | 2022-05-26 | Combocap, Inc. | Capsule with internal diaphragm for improved bioavailability |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0804968D0 (en) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peters et al. | Nutritional aspects of the prevention and treatment of osteoporosis | |
| Stránský et al. | Nutrition as prevention and treatment of osteoporosis | |
| EP1748705B1 (en) | Use of beta-cryptoxanthin | |
| Hagey et al. | Role of exercise and nutrition in menopause | |
| CN102325468B (en) | It is the nutritious supplementary pharmaceutical of more than 50 years old individual raising vigor, immunity, eye and bone health | |
| EA023843B1 (en) | Refreshing beverage | |
| US20130101569A1 (en) | Hair growth stimulant | |
| GB2585619A (en) | A supplement | |
| Bartolozzi | The natural approach to osteoporosis | |
| Charlton | Eating well: ageing gracefully! | |
| Phillips | Nutrition for healthy ageing | |
| GB2458467A (en) | Dietary supplement for maintenance of bone health | |
| TWI612905B (en) | A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
| WO2014016627A1 (en) | Vitamin and mineral preparations for gravidae for use in trimesters of pregnancy | |
| Chaudhary et al. | Avocado: the holistic source as a natural doctor | |
| Joshi et al. | Vitamins and minerals in the elderly | |
| CN106036387A (en) | Super chenopodium quinoa willd nutritional packet for promoting growth of children | |
| JP2018172346A (en) | Pregnancy support composition | |
| Gangwar | Formulation of Lichen Based Pill a Natural Source of Vitamin D3 with a High Absorption Rate by Ambrosiya Neo-Medicine Pvt. Ltd | |
| abbas Fadhil | The Effect of Vitamin D Deficiency in Women and its Symptoms and Treatment Methods | |
| CN105995674A (en) | Compound nutrient formula containing dunaliella salina | |
| Zhubi et al. | RECOMMENDATIONS AND USE OF CALCIUM, VITAMIN D, AND RECOMMENDED APPROPRIATE NUTRITION IN PATIENTS WITH RHEUMATOID DISEASES. | |
| US9326997B2 (en) | Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea | |
| CA2830275C (en) | Omega 3-fatty acid emulsion | |
| CA2517537A1 (en) | Potassium taurate bicarbonate and ascorbate complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R108 | Alteration of time limits (patents rules 1995) |
Free format text: EXTENSION APPLICATION Effective date: 20121115 Free format text: EXTENSION ALLOWED Effective date: 20130118 |
|
| R108 | Alteration of time limits (patents rules 1995) |
Free format text: EXTENSION ALLOWED Effective date: 20130318 Free format text: EXTENSION APPLICATION Effective date: 20130121 |
|
| R108 | Alteration of time limits (patents rules 1995) |
Free format text: EXTENSION APPLICATION Effective date: 20130314 Free format text: EXTENSION ALLOWED Effective date: 20130518 |
|
| APTC | Appeals to the court |
Free format text: APPEAL LODGED; APPEAL AGAINST THE DECISION OF THE COMPTROLLER DATED 23 MAY 2013 LODGED WITH THE COURT OF APPEAL ON 11 JULY 2013. |
|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |